![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Background: There have been concerns about the cardiovascular safety of omalizumab.
Objectives: In this study, the clinical status of the omalizumab receiving severe asthma patients and the cytokine expressions patterns were investigated.
Materials and methods: In a pilot study described below we examined the levels of serum eosinophil cationic peptid (ECP), CD200, d-dimer, 25-hydroxyvitamin D (25(OH)D), CXCL8 and IL-1β in asthma patients treated with anti-IgE therapy, to explore their relationship with disease activity, and the impact of anti-IgE therapy impact on those levels. Exercise stress testing and blood samples were taken at all follow up visits from the time of first diagnosis and after 20 months of treatment during the disease remission.
Results: Fractional exhaled nitric oxide concentrations and serum levels of sTRAIL, sCD200, D-dimer, ECP, total IgE, IL-1β and Hs-CRP were decreased while CXCL8, 25(OH)D were increased after starting the treatment of anti-IgE. Our first case of a patient, who had both protein C and S deficiency and hence a high risk for thromboembolism, documents for the first time the safety of omalizumab for asthmatic patients with concurrent risk factors contributing to arteriothrombotic events.
Conclusion: Omalizumab might be used carefully in patients with cardiovascular diseases.
Acknowledgments
Conception and study design: AD Yalcin; clinical follow-up: AD Yalcin, F Herth; analysis of data: AD Yalcin; contribution of reagents/materials: AD Yalcin; writing the paper: AD Yalcin, A Cilli, LG Strauss; revising the manuscript: A Bisgin. The authors would like to thank Dr. Saadet Gumuslu and Dr. Olcay Yegin for their helpful suggestions and laboratory permissions and Gizem Esra Genc for her laboratory assistance.